<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200111046082N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-04-10</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>Determining the Efficacy of Brain Electrical Stimulation in Shortening the Hospitalization of Patients With drug resistant epilepsy</public_title>
      <acronym></acronym>
      <scientific_title>The Efficacy of   High Definition anodal transcranial direct current stimulation in  shortening  of duration of hospitalization in Epilepsy Monitoring Unit of  patients with drug-resistant epilepsy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-06-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/46771</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, patients were randomly divided into two groups of 20 each. Randomization was performed using random sequencing with the help of SAS statistical software. Patients were divided into treatment and control groups according to the order of entry based on this sequence. Sealed envelopes were used to hide random allocation, Blinding description: Patients, main investigator and data analyser were masked of patients allocation. patients did not know the name of group and treatments. we used Sham for patients in control group. all questionnaire completed in different periods without name and only the related nurse know the patients allocations.</study_design>
      <phase>N/A</phase>
      <hc_freetext>drug resistant epilepsy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Twenty patients diagnosed with drug-resistant epilepsy will be studied according to the definition of the International league against Epilepsy (ILAE) after approval by the Ethics and Signature of consent. In all patients with possible epileptogenic zone according to semiology. The patient's previous epilepsy and lumbar strips are localized, and epileptogenic lesions are diagnosed by MRI of the brain with epilepsy protocols. Their antiepileptic drugs are discontinued during hospitalization in the EMU. Participants are randomly assigned to the experimental or sham group. Ten participants (experimental group) performed HD a-tDCS intervention in a current of 2 mA to fashion. They receive 30 minutes on the second day of hospitalization in the EMU twice in 4 hours on the epileptogenic zone. Intervention 2: Control group: Twenty patients diagnosed with drug-resistant epilepsy will be studied according to the definition of the International league against Epilepsy (ILAE) after approval by the Ethics and Signature of consent. In all patients with possible epileptogenic zone according to semiology. The patient's previous epilepsy and lumbar strips are localized, and epileptogenic lesions are diagnosed by MRI of the brain with epilepsy protocols. Their antiepileptic drugs are discontinued during the hospitalization period in the EMU. Ten people (sham group) receive sham tDCS using the same position of the electrode.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is undecided</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Soheila Rezakhani Jafarabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vice-challenger of Research, Ebn-e sina St., Jahad blvd.</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7619813159</zip>
        <telephone>+98 34 3226 3855</telephone>
        <email>drrezakhani@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Soheila Rezakhani Jafarabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kerman Neuroscience Research Center, Ebn Sina st., Jehad Blvd, Kerman, Iran</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7619813159</zip>
        <telephone>+98 34 3226 4196</telephone>
        <email>drrezakhani@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with drug-resistant epilepsy as defined by the International League against epilepsy (ILAE)
Over 18 years old
In all patients, the probable epileptogenic zone is localized according to the epilepsy semiology and  consecutive previous EEGs, and epileptogenic lesions are diagnosed by brain MRI with epilepsy protocol.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Under 18 years old
generalized epilepsy
scalp diseases such as eczema , cutaneous lesions ,
previous intracranial surgery
previous intracranial surgery, intracranial metal (out of mouth) such as tracking, surgical clip
implanted device such as cardiac pace maker, VNS, cochlear implant
severe and recurrent headaches</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G40.21</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Twenty patients diagnosed with drug-resistant epilepsy will be studied according to the definition of the International league against Epilepsy (ILAE) after approval by the Ethics and Signature of consent. In all patients with possible epileptogenic zone according to semiology. The patient's previous epilepsy and lumbar strips are localized, and epileptogenic lesions are diagnosed by MRI of the brain with epilepsy protocols. Their antiepileptic drugs are discontinued during hospitalization in the EMU. Participants are randomly assigned to the experimental or sham group. Ten participants (experimental group) performed HD a-tDCS intervention in a current of 2 mA to fashion. They receive 30 minutes on the second day of hospitalization in the EMU twice in 4 hours on the epileptogenic zone.</i_keyword>
      <i_keyword>Control group: Twenty patients diagnosed with drug-resistant epilepsy will be studied according to the definition of the International league against Epilepsy (ILAE) after approval by the Ethics and Signature of consent. In all patients with possible epileptogenic zone according to semiology. The patient's previous epilepsy and lumbar strips are localized, and epileptogenic lesions are diagnosed by MRI of the brain with epilepsy protocols. Their antiepileptic drugs are discontinued during the hospitalization period in the EMU. Ten people (sham group) receive sham tDCS using the same position of the electrode.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Investigating changes in hospitalization duration in epilepsy monitoring unit. Timepoint: The frequency of epileptic seizures will be recorded in both groups for 7 days. Method of measurement: Record the number of attacks.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-01-27</approval_date>
        <contact_name>Ethics committee of Kerman university of Medical Sciences</contact_name>
        <contact_address>Vice-challenger of Research, Ebn-e sina St., Jahad blvd. Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
